Malaria and COVID-19

Product Development Partnerships like MMV are contributing in important ways to the global effort against COVID-19. 

Over recent years MMV has developed end-to-end capabilities spanning drug discovery, development and delivery, that have brought new malaria medicines to millions in need. Now these capabilities are more crucial than ever. Early on MMV adapted its work plan for anticipated pandemic-related delays, while accelerating other areas of work to ensure that we could emerge with the strongest possible malaria portfolio. In parallel, MMV also reprioritized its areas of strategic focus for 2020 to include support for the COVID-19 effort.

Below you will find resources on MMV's activities in the context of COVID-19 as well as partner content on COVID-19 and malaria. 

Largest clinical trial in Africa to treat COVID-19 cases before they become severe

MMV and partners from the ANTICOV consortium launch the largest COVID-19 clinical trial in mild-to-moderate outpatients in Africa. The trial aims to respond to the urgent need to identify treatments and prevent spikes in hospitalization that could overwhelm fragile and already overburdened health systems in Africa.

MMV's activities in the context of COVID-19 - a letter from our CEO David Reddy

Over the years MMV has developed capabilities that have brought new malaria medicines to over 2 million people. These efforts in malaria are more crucial now than ever. Read more on MMV’s “pivot” of activities towards those that could have greatest impact in the context of the COVID-19 pandemic.

Rising to the dual challenge of malaria and COVID-19 in rural Zambia

Chola, a Community Facilitator from Serenje District, Zambia, found himself playing a key role in his community when COVID-19 was declared a pandemic in early 2020. This is his story.

 

 

MMV launches the COVID Box to stimulate new drug research

The COVID Box was dispatched on request and free-of-charge to accelerate open research into treatments for COVID-19 and other SARS coronaviruses. The aim was to catalyse the discovery of drugs for COVID-19 disease by providing researchers with an initial set of 80 marketed drugs or compounds in development with known or predicted activity against the coronavirus SARS-CoV-2.

Video: Malaria in times of COVID-19

Over the last 20 years, the global malaria community has made immense progress in the prevention and treatment of the disease. But this year, COVID-19 is threatening all that we have achieved so far. Watch this film to know about key areas where efforts need to continue, so that we can continue saving lives.

WHO's Q&A on malaria and the COVID-19 pandemic

WHO is continuously monitoring and responding to the COVID-19 pandemic. This Q&A will be updated as more is known about the novel coronavirus, how it spreads and how it is affecting malaria responses worldwide.

 

Malaria and COVID-19 infographic by RBM Partnership to End Malaria

COVID-19 is a disease that has spread quickly to all corners of the globe, presenting an emerging threat to millions of families at risk of malaria, fragile health systems in malaria-affected countries and decades of progress against malaria. Take a look at RBM Partnership to End Malaria's infographic to learn more.